Matt Layton, M.D., Ph.D. Clinical Associate Professor, WWAMI (Washington-Wyoming-Alaska Montana-Idaho) Medical Education Program, Washington State University-Spokane
Medical Director for the Program of Excellence in the Addictions and Leadership Team Member, Program of Excellence in Rural Mental Health and Substance Abuse Treatment, College of Nursing, Washington State University-Spokane; Program Director, University of Washington Department of Psychiatry & Behavioral Sciences Residency Training Program – Spokane Track.
Dr. Layton completed residency training in Psychiatry at the University of Washington. He is certified by the American Board of Psychiatry and Neurology, and has obtained certification from the United States Drug Enforcement Agency as a buprenorphine provider for the treatment of opioid dependence. His Ph.D. is in Pharmacology, specifically related to glutamate- and gamma-aminobutyric acid (GABA)-mediated redox and oxidative stress phenomena associated with brain injury in rats. Active research projects include the study of neuroactive steroid hormones known to modulate glutamate and GABA receptors during acute smoking cessation, as well as during psychostimulant withdrawal from methamphetamine, in comparison to healthy control subjects.